Two-year results from Boston Scientific's PROMUS Element trial to be presented at ACC 2012

Boston Scientific Corporation (NYSE: BSX) releases its schedule of product-related clinical research at the 61th Annual Scientific Session of the American College of Cardiology/i2 Summit, March 24-27 in Chicago.

"Two-year results from the PLATINUM Workhorse clinical trial will provide important follow-up data on our next-generation PROMUS Element™ Everolimus-Eluting Platinum Chromium Stent," said Keith D. Dawkins, M.D., Global Chief Medical Officer for Boston Scientific.  "Additional analysis from the PLATINUM and PERSEUS trials will provide further insight into the performance of our platinum chromium stent platform."

Schedule of Events

Saturday, March 24

• PROTECT AF Quality of Life Assessment.  David Holmes, M.D., the Global Principal Investigator of the PROTECT AF clinical trial, will present data assessing the Quality of Life of 527 patients that received the WATCHMAN® left atrial appendage closure device versus those randomized to warfarin.  The PROTECT AF trial demonstrated the WATCHMAN device was non-inferior to long-term warfarin therapy for stroke prevention.  Results will be presented starting at 9:30 a.m. during a poster session in Hall A.

Sunday, March 25

• PLATINUM/PERSEUS Longitudinal Stent Deformation Analysis.  Dean Kereiakes, M.D., the Principal Investigator of the PERSEUS clinical program, will present the largest systematic independent core laboratory analysis to date evaluating the incidence of longitudinal stent deformation in 2,403 patients treated with single stents in the PLATINUM and PERSEUS randomized clinical trials.  Outcomes will compare the PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent System to the PROMUS® (XIENCE V®) Everolimus-Eluting Coronary Stent System and the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System (TAXUS® Element™) to the TAXUS Express® Paclitaxel-Eluting Coronary Stent System.  Results will be presented at 11:00 a.m. during an oral presentation in Room S101a.  The Company plans to issue a press release announcing study results at this time.
• PLATINUM Workhorse two-year outcomes.  Gregg Stone, M.D., the Global Principal Investigator of the PLATINUM clinical program, will present two-year results from the PLATINUM Workhorse trial.  The randomized, controlled trial enrolled 1,530 patients at 132 sites worldwide and compares the PROMUS Element Everolimus-Eluting Platinum Chromium Coronary Stent System to the PROMUS (XIENCE V) Everolimus-Eluting Coronary Stent System.  Results will be presented at 11:45 a.m. during an oral presentation in Room S101a.  The Company plans to issue a press release announcing trial results at this time.

Monday, March 26

• SMART-AV Impact of Electrical Delay on AV Optimization.  Michael Gold, M.D., will present results on the impact of left ventricular electrical delay (QLV) on the benefit of SmartDelay™ optimization during cardiac resynchronization therapy.  SMART-AV is a randomized three-armed trial designed to investigate the effects of optimizing AV delay timing in heart failure patients receiving CRT-D therapy.  Results will be presented during a moderated poster session starting at 9:30 a.m. in Hall A.

Boston Scientific will present its latest cardiology, rhythm and vascular products at booth #3063 in the Exhibit Hall.